Volume 7, Number 1—February 2001
Research
Lack of Evidence of Endogenous Avian Leukosis Virus and Endogenous Avian Retrovirus Transmission to Measles Mumps Rubella Vaccine Recipients
Althaf I. Hussain*, Vedapuri Shanmugam*, William M. Switzer*, Shirley X. Tsang*, Aly Fadly†, Donald Thea‡, Rita Helfand*, William J. Bellini*, Thomas M. Folks*, and Walid Heneine*
Table
Western blot antibody reactivity to the p27 gag protein of the endogenous avian leukosis virus (ALV) in vaccine recipients and other reference chicken and human sera
| Sera tested | p27 Positive |
|---|---|
| Chicken sera (n = 61) | |
| ALV infected/antibody positivea | 27/27 |
| ALV uninfected/antibody negativea | 0/34 |
| REVb infected | 0/10 |
| Human sera (n = 68) | |
| Blood donors | 0/60 |
| HIV-1/2b positive | 0/4 |
| HTLV-I/IIb positive | 0/4 |
| MMRb vaccine recipients (n = 206) | |
| 6-12 monthsc | 0/32 |
| 12-30 monthsc | 0/158 |
| 6-12 monthsd | 0/16 |
aantibody reactivity to ALV determined by virus neutralization assays.
bREV = reticuloendotheliosis virus; HIV-1/2 = human immunodeficiency virus type 1 or 2; HTLV-I/II = human T-cell lymphotropic virus type 1 or 2; MMR = measles, mumps and rubella.
csamples collected after first MMR vaccination.
dsamples collected after second MMR vaccination.
Page created: March 16, 2011
Page updated: March 16, 2011
Page reviewed: March 16, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.